Mr. Su joined the Board of Directors of SHL as a Director in May 2017. Mr. Su is the Vice Chairman of the Board of Directors of Shenzhen Yanghe Biomedicine Industry Investment Co., Ltd. in China since 2013. Since 2002, Mr. Su served in various executive positions in Zhuhai Hokai Medical Instruments Co., Ltd., a leading public listed Chinese medical device company, as its Board member, Vice President and Board Secretary from 2007 to November 2013. From 1995 to 2002, Mr. Su was the Manager of Business Development Department, Credit Department and Legal Affairs Department of Zhuhai Branch, the Bank of East Asia, Ltd., a bank based in Hong Kong. Mr. Su holds an MBA from Murdoch University, Australia. Nationality: Chinese.
Dr. Amir Lerman
Dr. Lerman joined the Board of Directors of SHL as a non-executive Director in 2016. Dr. Lerman is the Director of the Cardiovascular Research Center at the Mayo Clinic in Rochester (USA) since 2013. He is also the Program Director for vascular and valve, Center for Regenerative Medicine at the Mayo Clinic, since 2012, and Vice-Chair, Cardiovascular Department and chair for Cardiovascular research at the Mayo Clinic, since 2013. In addition, Dr. Lerman serves as the Director of the Mayo-Israeli start up company initiative as well as a faculty member at the Mirage Institute: US-Israel innovation bridge business leadership program, since 2009, in addition to various other positions held at the Mayo Clinic. Dr. Lerman also holds an appointment as Professor of Medicine at the Mayo Medical School since 2001. Dr. Lerman graduated from the Technion school of Medicine in Haifa Israel in 1985 and completed his training in internal medicine, cardiovascular diseases and invasive cardiology at the Mayo Clinic in 1994. Dr. Lerman published more than 500 manuscripts, book chapters and reviews; the NIH, AHA, and several foundations support his research. Nationality: American/ Israeli.
Ms. Shenlu Xu joined the Board of Directors of SHL as a Director in May 2017. Ms. Xu is currently pursuing a Juris Doctor degree at Harvard Law School where she focuses her studies on corporate transactions and corporate governance. Previously, Ms Xu obtained a Bachelor of Business Administration (Accounting and Finance) from University of Hong Kong where she was awarded several scholarships and graduated with first class honors.
She has years of experience in investing in the stock market and has interned with various financial institutions and law firms, such as Simpson Thacher & Bartlett LLP, Taikang Asset Management, Himalaya TMT Fund and Hadef & Partners. Ms. Xu is the daughter of Mr. Xu Xiang, who is the Managing Director of Himalaya Asset Management Limited.
Nationality: Hong Kong SAR, China.
Mr. Wu joined the Board of Directors of SHL as a Director in May 2017. He is the Vice President and CTO of the Beijing Hospmall Technology Co., Ltd. which is a leading internet medical company in China since 2014. Prior to that, he served as Senior Manager and Chief Architect in Digital Film Research Institute of Dadi Culture Communication Group, and Project Manager in Research and Development Center of Toshiba (China).
Mr. Wu has many years of experience in system architecture design and software development, as well as in technical team management and project management. Mr. Wu holds a Bachelor degree from National University of Defense Technology, a Master degree from Tsinghua University, and a Doctor degree from Beijing Normal University, China.